Medicine
Synjardy 5 mg/500 mg tablet
Synjardy 5 mg/500 mg tablet is a prescription medicine containing Empagliflozin and Metformin for oral use, marketed by Boehringer Ingelheim Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Empagliflozin and Metformin
- Brand
- Synjardy
- Strength
- 5 mg/500 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 180 tablets, 60 tablets
- Marketing authorisation holder
- Boehringer Ingelheim Pharmaceuticals
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BD20 Empagliflozin and Metformin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 26 August 2015
- Identifiers
- RxCUI 1664315, 1664321, 1664323 +5DailyMed set ID 0fdd0255-0055-65f3-b2c0-db8fbb87beaeNDC 0597-0159Application NDA206111
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 180 tablet in 1 bottle | 0597-0159-18 | Boehringer Ingelheim Pharmaceuticals | 12 September 2015 |
| 60 tablet in 1 bottle | 0597-0159-60 | Boehringer Ingelheim Pharmaceuticals | 12 September 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Empagliflozin and Metformin
Clinical summary
Empagliflozin and Metformin is a fixed-dose combination of a biguanide and a sodium-glucose cotransporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults, among other approved uses. MedsAcross supplies Empagliflozin and Metformin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Empagliflozin and MetforminFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Synjardy prescribing information (Boehringer Ingelheim Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Synjardy: European public assessment report (EPAR) · European Medicines Agency
Need Synjardy 5 mg/500 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.